Drug delivery issues in vaccine development

Pharmaceutical Research

Volumn 13, Issue 12, 1996, Pages 1777-1785

  Powell, Michael F ^a  

^a GENENTECH INC   (United States)

Author keywords

Cytokines; DNA vaccines; Single shot vaccines; Sterilizing immunity; Targeted drug delivery; Therapeutic cancer vaccines; Vaccines

Indexed keywords

ADJUVANT; CANCER VACCINE; CYTOKINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VACCINE;

DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG TARGETING; HUMAN; IMMUNITY; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

AIDS VACCINES; ANIMALS; CANCER VACCINES; CYTOKINES; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; IMMUNIZATION; VACCINES; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0030444799     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016064504346     Document Type: Review

References (133)

1. S. A. Plotkin and E. A. Mortimer. Vaccines. Philadelphia: Saunders, (1988).
2. E. Brown, G. Dougan, E. M. Hoey, S. J. Martin, B. K. Rima, and A. Trudgett. Vaccine Design. New York: Wiley & Sons, (1993).
3. R. B. Fisher. Edward Jenner 1749-1823. St. Edmunds, Suffolk: St. Edmundsbury Press, pp. 361 (1991).
4. S. L. Plotkin and S. A. Plotkin. A short history of vaccination. In: S. A. Plotkin, E. A. Mortimer, (eds.) Vaccines. Philadelphia: Saunders, pp. 1-11 (1994).
5. D. P. Francis. Laboratory empiricism, clinical design, and social value. In: M. F. Powell, M. J. Newman, (eds.) Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, pp. 135-139 (1995).
6. P. Aaby. Malnutrition and overcrowding/intensive exposure in severe measles infection: Review of community studies. Rev. Infect. Dis. 10:478-49 (1988).
7. I. M. Longini-Jr. M. E. Halloran, M. Haber, and R. T. Chen. Measuring vaccine efficacy from epidemics of acute infectious agents. Stat. in Medicine 12:249-263 (1993).
8. L. B. Schonberger, J. E. McGowan-Jr., and M. B. Gregg. Vaccine-associated poliomyelitis in the United States. Am. J. Epidemiology 104:202-211 (1976).
9. H. V. Wyatt. Polio immunization: Benefits and risks. J. Family Practice 3 (1978).
10. M. J. Newman and M. F. Powell. Immunological and formulation design considerations for subunit vaccines. In: M. F. Powell, M. J. Newman, (eds.) Vaccine Design: The Subunit and Adjuvant Approach. Vol. 6. New York: Plenum Press, pp. 1-42 (1995).
11. J. L. Cleland, M. F. Powell, A. Lim, L. Barron, P. W. Berman, D. J. Eastman, J. H. Nunberg, T. Wrin, and J. C. Vennari. Development of a single-shot subunit vaccine for HIV-1. AIDS Res. Human Retrovir. 10:S21-S26 (1994).
12. J. L. Cleland, L. Barrón, P. W. Berman, A. Daugherty, T. Gregory, A. Lim, J. Vennari, T. Wrin, and M. F. Powell. Development of a single-shot subunit vaccine for HIV-1: Part 2. Defining optimal autoboost characteristics to maximize the humoral immune response. J. Pharm. Sci. (1996) (in press).
13. J. L. Cleland, L. Barrón, A. Daugherty, D. Eastman, C. Kensil, A. Lim, R. P. Weissburg, T. Wrin, J. Vennari, and M. F. Powell. Development of a single-shot subunit vaccine for HIV-1: Part 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J. Pharm. Sci. (1996) (in press).
14. J. L. Cleland, M. F. Powell, A. Lim, L. Barrón, P. W. Berman, J. H. Nunberg, D. J. Eastman, T. Wrin, J. C. Vennari, K. K. Murthy, C. R. Kensil, and J. Y. Wu. Development of a single administration subunit vaccine for HIV-1. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22:570-571 (1995).
15. J. L. Cleland, A. Lim, A. Daugherty, L. Barrón, N. Desjardin, E. T. Duenas, D. J. Eastman, J. C. Vennari, T. Wrin, P. Berman, K. K. Murthy, and M. F. Powell. Development of a single-shot subunit vaccine for HIV-1: Part 5. Programmable in vivo auto boost and long lasting neutralizing response. In preparation, 1996.
16. J. L. Cleland, A. Lim, L. Barrón, E. T. Duenas, and M. F. Powell. Development of a single-shot subunit vaccine for HIV-1: Part 4. Optimizing microencapsulation on pulsatile release of MN gp 120 from biodegradable microspheres. J. Pharm. Sci., (1996) (in press).
17. J. H. Eldridge, J. K. Staas, J. A. Meulbroek, J. R. McGhee, T. R. Tice, and R. M. Gilley. Biodegradable microspheres as a vaccine delivery system. Molecular Immunology 28:287-294 (1991).
18. D. T. O'Hagan, D. Rahman, J. P. McGee, H. Jeffery, M. C. Davies, P. Williams, S. S. Davis, and S. J. Challacombe. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73:239-242 (1991).
19. J. Hanes, M. Chiba, and R. Langer. Polymer microspheres for vaccine delivery. In: M. F. Powell, M. J. Newman, (eds.) Vaccine Design: The Subunit and Adjuvant Approach. Vol. 6. New York: Plenum Press, pp. 389-412 (1995).
20. J. L. Cleland. Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems. In: M. F. Powell, M. J. Newman, (eds.) Vaccine Design: The Subunit and Adjuvant Approach. Vol. 6. New York: Plenum Press, pp. 439-462 (1995).
21. W. R. Gombotz, M. S. Healy, and L. R. Brown. Very low temperatures casting of controlled release microspheres. ( 1991 ). Enzytech, Inc. 5/28/91 Patent #5019400.
22. M. F. Powell, J. L. Cleland, and S. J. Shire. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Them. Drug Carr. Sys. 10:307-377 (1993).
23. B. Gander, C. Thomasin, H. P. Merkle, Y. Men, and G. Corradin. Pulsed tetanus toxoid release from PLGA-microspheres and its relevance for immunogenicity in mice. Proc. Int. Symp. Control. Rel. Bioact. Mater. Washington DC: Controlled Release Society, pp. 65-66 (1993).
24. R. A. Miller, J. M. Brady, and D. E. Cutright. Degradation rates of oral resorbable implants (polylactates and poly glycolates): Rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res. 11:711-719 (1977).
25. R. A. Kenley, M. O. Lee, T. R. Mahoney-II, and L. M. Sanders. Poly(lactide-co-glycolide) decomposition kinetics in vivo and in vitro. Macromolecules 20:2398-2403 (1987).
26. W. W. Wong, S. Vijayakumar, and R. R. Weichselbaum. Prognostic indicators in node-negative early stage breast cancer. Am. J. Med. 92:539-548 (1992).
27. G. J. V. Nossal. Molecular and cellular aspects of immunologic tolerance. Eur. J. Biochem. 202:729-737 (1991).
28. S. Adelstein, H. Pritchard-Briscoe, T. A. Anderson, J. Crosbie, G. Gammon, R. H. Loblay, A. Basten, and C. C. Goodnow. Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen. Science 251:1223-1225 (1991).
29. J. L. Urban, and H. Schreiber. Tumor antigens. J. Immunology 10:617-644 (1992).
30. M. G. Brown, J. Driscoll, and J. J. Monaco. Structural and serological similarity of MHC-linked LMP and proteosome (multicatalytic proteinase) complexes. Nature 353:335-357 (1991).
31. C. K. Martinez, and J. J. Monaco. Homology of proteosome subunits to a major histocompatibility complex-linked LMP gene. Nature 353:664-667 (1991).
32. A. L. Goldberg, and K. L. Rock. Proteolysis, proteosomes and antigen presentation. Nature 357:375-379 (1992).
33. J. J. Monaco, S. Cho, and M. Attaya. Transport proteins in the murine MHC: Possible implications for antigen processing. Science 250:1723-1726 (1990).
34. A. Kelly, S. H. Powis, L. Kerr, I. Mockridge, T. Elliott, J. Bastin, B. Uchanska-Ziegler, A. Ziegler, and A. Townsend. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 355:641-644 (1992).
35. T. Spies, V. Cerundolo, M. Colonna, P. Cresswell, A. Townsend, and R. DeMars. Presentation of viral antigen by class I MHC molecules is dependent on a putative peptide transporter heterodimer. Nature 355:644-646 (1992).
36. W. Suh, M. F. Cohen-Doyle, K. Fruh, K. Wang, P. A. Peterson, and D. B. Williams. Interaction of MHC class I molecules with the transporter associated with antigen processing. Science 264:1322-1326 (1994).
37. E. Degen, and D. B. Williams. Participation of a novel 88 kD protein in the biogenesis of murine class I histocompatibility molecules. J. Cell. Biol. 112:1099-1115 (1991).
38. M. R. Jackson, M. F. Cohen-Doyle, P. A. Peterson, and D. B. Williams. Regulation of MHC class I transport by the molecular chaperon, calnexin (p88, IP90). Science 263:384-387 (1994).
39. K. Falk, O. Rotzschke, and H. Rammensee. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348:248-251 (1990).
40. K. Falk, O. Rotzschke, S. Stevanovic, G. Jung, and H. G. Rammensee. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-295 (1991).
41. b molecule. Nature 348:213-216 (1990).
42. O. Rotzschke, K. Falk, O. Deres, H. Schild, M. Norda, J. Metzger, G. Jung, and H. Rammensee. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-253 (1990).
43. D. S. Collins, E. R. Unanue, and C. V. Harding. Reduction of disulfide bonds within lysosomes is a key step in antigen processing. J. Immunol. 147:4054-4059 (1991).
44. J. M. van-Noort, J. Boon, A. C. M. Van-der-Drift, J. P. A. Wagenaar, A. M. H. Boot, and C. J. P. Goog. Antigen processing by endosomal proteases determines which sites on sperm-whale myoglobin are eventually recognized by T cells. Eur. J. Immunol. 21:1989-1996 (1991).
45. L. Vidard, K. L. Rock, and B. Benacerraf. The generation of immunogenic peptides can be selectively increase or decrease by proteolytic enzyme inhibitors. J. Immunol. 147:1786-1791 (1991).
46. B. Bennett, I. J. Check, M. R. Olsen, and R. L. Hunter. A comparison of commercially available adjuvants for use in research. J. Immunol. Meth. 153:31-40 (1992).
47. P. J. Peters, J. J. Neefjes, V. Oorschot, H. L. Ploegh, and H. J. Geuze. Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to the lysosomal compartments. Nature 349:669-676 (1991).
48. C. V. Harding, D. S. Collins, J. W. Slot, H. J. Geuze, and E. R. Unanue. Liposome-encapsulated antigens are processed in lysosomes, recycled and presented to T-cells. Cell 64:393-401 (1991).
49. J. J. Neefjes, V. Stollorz, P. J. Peters, H. J. Geuze, and H. L. Ploegh. The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell 61:171-183 (1990).
50. M. S. Anderson, and J. Miler. Invariant chain can function as a chaperon protein for class II major histocompatibility complex molecules. Proc. Natl. Acad. Sci. 89:2282-2286 (1992).
51. d binding peptides derived from unrelated proteins share a common structural motif. J. Immunol. 141:45-48 (1988).
52. d. Science 256:660-662 (1992).
53. A. Sette, J. Sidney, C. Oseroff, M. del-Guerico, S. Southwood, T. Arrhenius, M. F. Powell, S. M. Colon, F. C. A. Gaeta, and H. M. Grey. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J. Immunology 151:3163-3170 (1993).
54. C. H. Kensil, U. Patel, M. Lennick, and D. Marciani. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J. Immunol. 146:431-437 (1991).
55. J. Wu, B. H. Gardiner, C. I. Murphy, J. R. Seals, C. R. Kensil, J. Recchia, G. A. Beltz, G. W. Newman, and M. J. Newman. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 148:1519-1525 (1992).
56. + cytotoxic T lymphocyte responses. J. Immunology 148:2357-2362 (1992).
57. L. J. Old. Cancer immunology: The search for specificity-GHA Clowes Memorial Lecture. Cancer Res. 41:361-375 (1981).
58. K. S. Furukawa, K. Furukawa, F. X. Real, L. J. Old, and K. O. Loyd. A unique antigenic epitope of human melanoma is carried on the common melanoma glycoprotein gp95/p97. J. Exp. Med. 169:585-590 (1989).
59. A. Ryghetti, V. Turchi, C. A. Ghetti, G. Scambia, P. B. Panici, G. Roncucci, S. Mancuso, L. Frati, and M. Nuti. Human B cell immune response to the polymorphic epithelial mucin. Cancer Res. 53:2457-2459 (1993).
60. P. O. Livingston, E. J. Natoli-Jr., M. J. Calves, E. Stockert, H. F. Oettgen, and L. J. Old. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. 84:2911-2915 (1987).
61. J. Bystryn, S. Ferrone, and P. Livingston. Specific Immunotherapy of Cancer with Vaccines. Vol. 690: New York, pp. 411 (1993).
62. D. L. Morton, L. J. Foshag, D. S. B. Hoon, J. A. Nizze, E. Famatiga, L. A. Wanek, C. Chang, D. G. Davtyan, R. K. Gupta, R. Elashoff, and R. F. Irie. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216:463-482 (1992).
63. D. Berd, H. C. Maguire-Jr., P. McCue, and M. J. Mastrangelo. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J. Clin. Oncol. 8:1858-1867 (1990).
64. P. Mersey, A. Edwards, A. Coates, H. Shaw, W. H. McCarthy, and G. W. Milton. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol. Immunother. 25:257-265 (1987).
65. L. G. Durrant, G. W. L. Denton, and R. A. Robins. Immunization with human monoclonal antiidiotypic antibody in colorectal cancer. In: J. Bystryn, S. Ferrone, P. Livingston (eds.) Specific Immunotherapy of Cancer with Vaccines. Vol. 690. New York: NY Acad. Sci., pp. 334-342 (1993).
66. M. R. Hilleman. The promise and the reality of viral vaccines against cancer. In: J. Bystryn, S. Ferrone, P. Livingston (eds.) Specific Immunotherapy of Cancer with Vaccines. Vol. 690. New York: NY Acad. Sci., pp. 6-18 (1994).
67. A. J. McMichael and W. F. Bodmer. A New Look at Tumor Immunology. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press, (1992).
68. T. Boon. Teaching the immune system to fight cancer. Sci. Am. 266:82-89 (1993).
69. B. M. Longenecker, M. Reddish, R. Koganty, and G. D. MacLean. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus Detox adjuvant. Ann. N. Y. Acad. Sci. 690:276-291 (1993).
70. D. M. Pardoll. Cancer vaccines. Immunol. Today 14:310-316 (1993).
71. See also: D. M. Pardoll, Cancer vaccines: A road map for the next decade. Curr. Opin. Immunol. 100:619-621 (1996).
72. H. N. Eisen, and G. W. Siskind. Variations in affinities of antibodies during the immune response. Biochemistry 3:996 (1964).
73. L. A. Steiner, and H. N. Eisen. The relative affinity of antibodies synthesized in the secondary response. J. Exp. Med. 126:1185-1205 (1967).
74. D. Salk, and J. Salk. Vaccinology of poliomyelitis. Vaccine 2:59-74 (1984).
75. V. A. Fulginiti. Immunizations: Current Controversies. J. Pediatr. 101:487-494 (1982).
76. M. Bruguera, M. Cremades, R. Salinas, J. Costa, M. Grau, and J. Sans. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J. Clin. Gastero. 14:27-30 (1992).
77. J. S. MacKenzie. Influenza subunit vaccine: Antibody responses to one and two dose of vaccine and length of response, with reference to the elderly. Br. Med. J. 1:200-202 (1977).
78. K. P. Anderson, C. Lucas, C. V. Hanson, H. F. Londe, A. Izu, T. Gregory, A. Ammann, P. W. Berman, and J. W. Eichberg. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J. Infect. Diseases 160:960-969 (1989).
79. M. F. Powell, and M. J. Newman. Vaccine Design: The Subunit and Adjuvant Approach. In: R. T. Borchardt, ed. Pharmaceutical Biotechnology. Vol. 6. New York: Plenum Press, pp. 949 (1995).
80. F. R. Vogel, and M. F. Powell. A compendium of vaccine adjuvants and excipients. In: M. F. Powell, M. J. Newman (eds.) Vaccine Design: The Subunit and Adjuvant Approach. Vol. 6. New York: Plenum Press, pp. 141-228 (1995).
81. W. E. Paul, and R. A. Seder. Lymphocyte responses and cytokines. Cell 76:241-251 (1994).
82. E. G. Pamer. Cellular immunity to intracellular bacteria. Curr. Opin. Immunol. 5:492-496 (1993).
83. S. H. E. Kaufmann. Immunity to intracellular bacteria. Annu. Rev. Immunol. 11:129-164 (1993).
84. B. S. Graham, G. S. Henderson, Y. Tang, X. Lu, K. M. Neuzil, and D. G. Colley. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040 (1993).
85. R. L. Modlin, and T. B. Nutman. Type 2 cytokines and negative immune regulation in human infections. Curr. Opin. Immunol. 5:511-517 (1993).
86. D. D. Ho, M. G. Sarngadharan, M. S. Hirsch, R. T. Schooley, T. R. Rota, R. C. Kennedy, T. C. Chanh, and V. L. Sato. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol. 61:2024-2028 (1987).
87. A. W. Heath. Cytokines as immunological adjuvants. In: M. F. Powell, M. J. Newman, (eds.) Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, pp. 645-658 (1995).
88. L. B. Lachman, L. Shih, X. Rao, S. E. Ullrich, and J. L. Cleland. Cytokine-containing liposomes as adjuvants for subunit vaccines. In: M. F. Powell, M. J. Newman, (eds.) Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, pp. 659-671 (1995).
89. W. H. Alwan, F. M. Record, and P. J. M. Openshaw. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J. Immunol. 150:5211-5218 (1993).
90. T. G. Terrell and J. D. Green. Comparative pathology of recombinant murine interferon-gamma in mice and recombinant human interferon-gamma in Cynomolgus Monkeys. Intl. Rev. Exp. Pathol. 34:73-101 (1993).
91. T. R. Mosmann and R. L. Coffman. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173 (1989).
92. G. Reibnegger, D. Fuchs, L. C. Fuith, A. Hausen, E. R. Werner, G. Werner-Felmayer, and H. Wachter. Neopterin as a marker for activated cell-mediated immunity: Application in malignant disease. Cancer Detection & Prevention 15:483-490 (1991).
93. J. D. Green and T. G. Terrell. Utilization of homologous proteins to evaluate the safety of recombinant human proteins - case study: Recombinant human interferon-gamma (rhIFN-g). Toxicology Letters 64/65:321-327 (1992).
94. P. Dong, C. Brunn, and R. J. Y. Ho. Cytokines as vaccine adjuvants: Current status and potential applications. In: M. F. Powell, M. J. Newman, (eds.) Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, pp. 625-643 (1995).
95. J. Vingerhoets, G. Vanham, L. Kestens, G. Penne, G. Leroux-Roels, and P. Gigase. Deficient T-cell responses in non-responders to hepatitis B vaccination: Absence of TH1 cytokine production. Immunol. Lett. 39:163-168 (1994).
96. F. R. Vogel, and N. Sarver. Nucleic acid vaccines. Clin. Microbiol. Rev. 8:406-410 (1995).
97. S. A. Johnston, and D. C. Tang. Gene gun transfection of animal cells and genetic immunization. Methods Cell Biol. 43:353-365 (1994).
98. N. R. Rabinovich, P. Mclnnes, D. L. Klein, and B. F. Hall. Vaccine technologies: View to the future. Science 265:1401-1404 (1994).
99. E. F. Fynan, R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro, and H. L. Robinson. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. 90:11478-11482 (1993).
100. M. Nakanishi. Gene introduction into animal tissues. Crit. Rev. Them. Drug Carr. Sys. 12:263-310 (1995).
101. E. F. Fynan, R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro, and H. L. Robinson. DNA vaccines: A novel approach to immunization. Intl. J. Immunopharmacol. 17:79-83 (1995).
102. M. D. Eisenbraun, D. H. Fuller, and J. R. Haynes. Examination of parameters affecting the elicitation of humoral immune response by particle bombardment-mediated genetic immunization. DNA & Cell Biol. 12:791-797 (1993).
103. A. R. Fooks, E. Schadeck, U. G. Liebert, A. B. Dowsett, B. K. Rima, M. Steward, J. R. Stephenson, and G. W. Wilkinson. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: Induction of an MHC-1-restricted CTL response and protection in a murine model. Virology 210:456-465 (1995).
104. D. R. Sizemore, A. A. Branstrom, and J. C. Sadoff. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270:299-302 (1995).
105. R. A. Spooner, M. P. Deonarain, and A. A. Epenetos. DNA vaccination for cancer treatment. Gene Therapy 2:173-180 (1995).
106. W. C. Lai, M. Bennett, S. A. Johnston, M. A. Barry, and S. P. Pakes. Protection against Mycoplasma pulmonis infection by genetic vaccination. DNA & Cell Biol. 14:643-651 (1995).
107. D. B. Lowrie, R. E. Tascon, M. J. Colston, and C. L. Silva. Towards a DNA vaccine against tuberculosis. Vaccine 12:1537-1540 (1994).
108. S. L. Hoffman, M. Sedegah, and R. C. Hedstrom. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. Vaccine 12:1529-1533 (1994).
109. W. Yang, G. J. Waine, and D. P. McManus. Antibodies to Schistosoma japonicum (Asian bloodfluke) paramyosin induced by nucleic acid vaccination. Biochem. Biophys. Res. Comm. 212:1029-1039 (1995).
110. M. Yokoyama, J. Zhang, and J. L. Whitton. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J. Virol. 69:2684-2688 (1995).
111. R. G. Webster, E. F. Fynan, J. C. Santoro, and H. Robinson. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 12:1495-1498 (1994).
112. D. H. Fuller, and J. R. Haynes. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Human Retrovir. 10:1433-1441 (1994).
113. A. Fomsgaard. Genetic immunization - "the biological equivalent of cold fusion?". Ugeskrift for Laeger 157:4932-4936 (1995).
114. M. Vitadello, M. V. Schiaffino, A. Picard, M. Scarpa, and S. Schiaffino. Gene transfer in regenerating muscle. Human Gene Therapy 5:11-18 (1994).
115. I. Danko, J. D. Fritz, S. Jiao, K. Hogan, J. S. Latendresse, and J. A. Wolff. Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Therapy 1:1-8 (1993).
116. R. J. Mannino, and S. Gould-Fogerite. Liposome mediated gene transfer. BioTechniques 6:682-690 (1988).
117. S. Jiao, P. Williams, R. K. Berg, B. A. Hodgeman, L. Liu, G. Repetto, and J. A. Wolff. Direct gene transfer into nonhuman primate myofibers in vivo. Human Gene Therapy 3:21-33 (1992).
118. M. J. Newman. Personal communication. (1996).
119. B. Wang, J. Boyer, V. Srikantan, K. Ugen, L. Gilbert, C. Phan, K. Dang, M. Merva, M. G. Agadjanyan, M. Newman, R. Carrano, D. McCallus, L. Coney, W. V. Williams, and D. B. Weiner. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology 211:102-112 (1995).
120. C. C. Zarozinski, E. F. Fynan, L. K. Selin, H. L. Robinson, and R. M. Welse. Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. J. Immunol. 154:4010-4017 (1995).
121. J. S. Robertson. Safety considerations for nucleic acid vaccines. Vaccine 12:1526-1528 (1994).
122. H. A. Smith. Regulatory considerations for nucleic acid vaccines. Vaccine 12:1515-1519 (1994).
123. D. P. Bolognesi. The dilemma of developing and testing AIDS vaccines. In: G. M. Cooper, R. G. Temin, B. Sugden, (eds.) The DNA Provirus: Howard Temin's Scientific Legacy. Washington DC: Amer. Soc. Microbiol., pp. 301-312 (1995).
124. S. H. Pincus, K. G. Messer, P. L. Nara, W A. Blattner, G. Colclough, and M. Reitz. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J. Clin. Investigation 93:2505-2513 (1994).
125. P. W. Berman, T. Matthews, D. Eastman, G. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant gp120 but not gp160. Nature 345:622-625 (1994).
126. P. W. Herman, K. K. Murthy, T. Wrin, J. Vennari, E. K. Cobb, D. J. Eastman, M. Champe, G. Nakamura, D. Davison, M. F. Powell, J. Bussiere, T. J. Gregory, T. Matthews, and J. F. Obijeski. Protection of MN-rgp120 immunized chimpanzees from heterologous infection with a primary isolate of HIV-1. J. Infect. Dis. (1995) (in press).
127. J. E. Salk. How many injections of poliomyelitis vaccine for effective and durable immunity? J.A.M.A. 167:1-7 (1958).
128. D. Salk, A. L. van Wezel, and J. Salk. Induction of long term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 2:1317-1321 (1984).
129. K. M. Zangwill, R. W. Stout, G. M. Carlone, L. Pais, H. Harekeh, S. Mitchell, W. H. Wolfe, V. Blackwood, B. D. Plikaytis, and J. D. Wenger. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J. Infect. Dis. 169:847-852 (1994).
130. Z. Mintai, L. Kezhou, D. Lieming, and R. A. Smego-Jr. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin. Infect. Dis. 16:165-167 (1993).
131. D. Lieming, Z. Mintai, W. Yinfu, Z. Shaochon, K. Weiqin, and R. A. Smego-Jr. A 9-year follow-up study of the immunogenecity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin. Infect. Dis. 17:475-479 (1993).
132. L. G. Payne, S. A. Jenkins, A. Andrianov, and B. E. Roberts. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. In: M. F. Powell, M. J. Newman, (eds.) Vaccine Design: The Subunit and Adjuvant Approach. Vol. 6. New York: Plenum Press, pp. 473-493 (1995).
133. D. Francis, P. W. Berman, J. L. Cleland, J. McElrath, T. J. Gregory, A. Lim, T. Wrin, J. Vennari, and M. F. Powell. Decay and persistence of the humoral immune response to recombinant MN gp120 in humans. (1996) In preparation.